Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease
Objective: Current evidence on the immunogenicity of influenza vaccination in patients with chronic obstructive pulmonary disease (COPD) is limited. To address this need for additional knowledge, we conducted a study on the immunogenicity of trivalent seasonal influenza vaccine (TIV) in COPD patient...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-09-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2021.1911515 |
_version_ | 1797674506120069120 |
---|---|
author | Yan Li Ying Ma Zhijie An Chenyan Yue Yamin Wang Yunqiu Liu Xiaodong Yuan Shuping Zhang Ming Shao Changgui Li Keli Li Zundong Yin Liye Wang Huaqing Wang |
author_facet | Yan Li Ying Ma Zhijie An Chenyan Yue Yamin Wang Yunqiu Liu Xiaodong Yuan Shuping Zhang Ming Shao Changgui Li Keli Li Zundong Yin Liye Wang Huaqing Wang |
author_sort | Yan Li |
collection | DOAJ |
description | Objective: Current evidence on the immunogenicity of influenza vaccination in patients with chronic obstructive pulmonary disease (COPD) is limited. To address this need for additional knowledge, we conducted a study on the immunogenicity of trivalent seasonal influenza vaccine (TIV) in COPD patients. Methods: We recruited patients from respiratory outpatient clinics of three hospitals in Tangshan, Hebei province who had stable confirmed COPD, were less than 80 y old, and reported not having had influenza or receiving TIV during the study season prior to enrollment. Patients who had a history of allergy to any TIV component or were classified as having very severe COPD were excluded from the study. Eligible and consenting participants were given one dose of TIV after obtaining a baseline blood sample. A second blood sample was obtained 5 weeks later. We used hemagglutination inhibition (HI) assays to measure antibody responses. We considered seropositive to be an HI titer ≥1:10. We considered seroprotection to be an HI titer ≥1:40 and seroconversion to be either a change from seronegative to a post-vaccination titer of ≥1:40 or a fourfold rise in antibody titer among baseline seropositive subjects. Each subject was followed for 1 month to assess the frequency and type of adverse events. Results: Eighty-eight subjects completed our study; the median age was 64 y; most (62.5%) had moderately severe COPD; 48.9% of the subjects had comorbid conditions in addition to COPD. Post–vaccination seropositive rates for influenza H1N1, H3N2, and B were all 100%; corresponding seroprotection rates were 96.6%, 93.2%, and 98.9%; seroconversion rates were 81.8%, 87.5%, and 75.0%. There were no statistical differences in seroconversion (P = .10) and seroprotection (P = .30) among the three types of influenza virus. Geometric mean titers (1:) of HI antibodies to H1N1, H3N2, and B were 18.8 (95% CI: 14.0–25.1), 12.2 (95% CI: 9.6–15.4), and 31.8 (95% CI: 26.1–38.8) at baseline, and 267.0 (95% CI: 213.8–333.4), 190.3 (95% CI: 151.7–238.6), and 201.1 (95% CI: 166.5-242.8) after vaccination. Conclusion: The immunogenicity of one dose of influenza vaccine was excellent in COPD patients. Our study supports recommending influenza vaccination for COPD patients to provide protection from influenza and its complications. |
first_indexed | 2024-03-11T22:01:02Z |
format | Article |
id | doaj.art-c6ba2afa020e4775870296f5f6070a3b |
institution | Directory Open Access Journal |
issn | 2164-5515 2164-554X |
language | English |
last_indexed | 2024-03-11T22:01:02Z |
publishDate | 2021-09-01 |
publisher | Taylor & Francis Group |
record_format | Article |
series | Human Vaccines & Immunotherapeutics |
spelling | doaj.art-c6ba2afa020e4775870296f5f6070a3b2023-09-25T11:19:18ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-09-011793131313610.1080/21645515.2021.19115151911515Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary diseaseYan Li0Ying Ma1Zhijie An2Chenyan Yue3Yamin Wang4Yunqiu Liu5Xiaodong Yuan6Shuping Zhang7Ming Shao8Changgui Li9Keli Li10Zundong Yin11Liye Wang12Huaqing Wang13National Immunization Program, Chinese Center for Disease Control and PreventionKailuan General HospitalNational Immunization Program, Chinese Center for Disease Control and PreventionNational Immunization Program, Chinese Center for Disease Control and PreventionNational Immunization Program, Chinese Center for Disease Control and PreventionKailuan General HospitalKailuan General HospitalKailuan General HospitalNational Institute for Food and Drug ControlNational Institute for Food and Drug ControlNational Immunization Program, Chinese Center for Disease Control and PreventionNational Immunization Program, Chinese Center for Disease Control and PreventionKailuan General HospitalNational Immunization Program, Chinese Center for Disease Control and PreventionObjective: Current evidence on the immunogenicity of influenza vaccination in patients with chronic obstructive pulmonary disease (COPD) is limited. To address this need for additional knowledge, we conducted a study on the immunogenicity of trivalent seasonal influenza vaccine (TIV) in COPD patients. Methods: We recruited patients from respiratory outpatient clinics of three hospitals in Tangshan, Hebei province who had stable confirmed COPD, were less than 80 y old, and reported not having had influenza or receiving TIV during the study season prior to enrollment. Patients who had a history of allergy to any TIV component or were classified as having very severe COPD were excluded from the study. Eligible and consenting participants were given one dose of TIV after obtaining a baseline blood sample. A second blood sample was obtained 5 weeks later. We used hemagglutination inhibition (HI) assays to measure antibody responses. We considered seropositive to be an HI titer ≥1:10. We considered seroprotection to be an HI titer ≥1:40 and seroconversion to be either a change from seronegative to a post-vaccination titer of ≥1:40 or a fourfold rise in antibody titer among baseline seropositive subjects. Each subject was followed for 1 month to assess the frequency and type of adverse events. Results: Eighty-eight subjects completed our study; the median age was 64 y; most (62.5%) had moderately severe COPD; 48.9% of the subjects had comorbid conditions in addition to COPD. Post–vaccination seropositive rates for influenza H1N1, H3N2, and B were all 100%; corresponding seroprotection rates were 96.6%, 93.2%, and 98.9%; seroconversion rates were 81.8%, 87.5%, and 75.0%. There were no statistical differences in seroconversion (P = .10) and seroprotection (P = .30) among the three types of influenza virus. Geometric mean titers (1:) of HI antibodies to H1N1, H3N2, and B were 18.8 (95% CI: 14.0–25.1), 12.2 (95% CI: 9.6–15.4), and 31.8 (95% CI: 26.1–38.8) at baseline, and 267.0 (95% CI: 213.8–333.4), 190.3 (95% CI: 151.7–238.6), and 201.1 (95% CI: 166.5-242.8) after vaccination. Conclusion: The immunogenicity of one dose of influenza vaccine was excellent in COPD patients. Our study supports recommending influenza vaccination for COPD patients to provide protection from influenza and its complications.http://dx.doi.org/10.1080/21645515.2021.1911515immunogenicitysafetytrivalent seasonal influenza vaccinechronic obstructive pulmonary disease |
spellingShingle | Yan Li Ying Ma Zhijie An Chenyan Yue Yamin Wang Yunqiu Liu Xiaodong Yuan Shuping Zhang Ming Shao Changgui Li Keli Li Zundong Yin Liye Wang Huaqing Wang Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease Human Vaccines & Immunotherapeutics immunogenicity safety trivalent seasonal influenza vaccine chronic obstructive pulmonary disease |
title | Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease |
title_full | Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease |
title_fullStr | Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease |
title_full_unstemmed | Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease |
title_short | Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease |
title_sort | immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease |
topic | immunogenicity safety trivalent seasonal influenza vaccine chronic obstructive pulmonary disease |
url | http://dx.doi.org/10.1080/21645515.2021.1911515 |
work_keys_str_mv | AT yanli immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease AT yingma immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease AT zhijiean immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease AT chenyanyue immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease AT yaminwang immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease AT yunqiuliu immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease AT xiaodongyuan immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease AT shupingzhang immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease AT mingshao immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease AT changguili immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease AT kelili immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease AT zundongyin immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease AT liyewang immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease AT huaqingwang immunogenicityoftrivalentseasonalinfluenzavaccineinpatientswithchronicobstructivepulmonarydisease |